Terpenoids comprise a structurally diverse group of natural products. Despite various and important uses of terpenoids (e.g., flavors, drugs, and nutraceuticals), most of them are, however, still extracted from plant sources, which suffer from high cost and low yield. Alternatively, terpenoids can be produced in microbes using their biosynthetic genes. With the explosion of sequence data, many genes for terpenoid metabolism can be characterized by biochemical approaches and used for the microbial production of terpenoids. However, substrates for in vitro studies of terpene synthases are costly, and the enzymatic synthesis of terpenoids in vitro using recombinant enzymes is insufficient to meet the chemical characterization need. Here, we describe the use of engineered yeast (EPY300) to evaluate in vivo production of sesquiterpenoids. Two sesquiterpene synthase genes (for valencene and 5-epi-aristolochene synthases) were expressed in EPY300 in native and N-terminal thioredoxin fusion forms. By using the thioredoxin fusion, valencene biosynthesis was slightly decreased; however, the production of 5-epi-aristolochene was increased by 10-fold, producing 420 μg mL(-1) of 5-epi-aristolochene. Accordingly, the thioredoxin-fused 5-epi-aristolochene was coexpressed with 5-epi-aristolochene dihydroxylase (cytochrome P450 monooxygenase) and its reductase in EPY300. This combinatorial expression yielded hydroxylated sesquiterpene, capsidiol, at ~250 μg mL(-1). Detailed experimental procedures and other considerations for this work are given.
Copyright © 2012 Elsevier Inc. All rights reserved.